Tumor necrosis factor identified in multiple sclerosis brain by unknown
TUMOR
NECROSIS FACTOR IDENTIFIED
IN
MULTIPLE SCLEROSIS BRAIN
BY
F
.
M
.
HOFMAN,' D
.
R
.
HINTON,' K
.
JOHNSON,' AND J
.
E
.
MERRILL
:
From
the 'Department of Pathology, University ofSouthern California School of Medicine
;
and
the DDppartment of Neurology, University of California at Los Angeles School of Medicine,
Los
Angeles, California 90033
Multiple
sclerosis (MS) is a disease characterized by focal perivascular inflamma-
tory
cell infiltrates and demyelination of the white matter in the central nervous system
(CNS).
At the plaque site, there may be a depletion ofoligodendroglial cells, prolifer-
ation
ofastrocytes, and an accumulation ofpositive macrophages (1-3)
.
In a previous
study,
we found the cells in the MS lesion to be IL-2-R+ cells, also staining for the
cytokines
IL-1, IL-2, and prostaglandin E (PGE) (4)
.
These results suggested that
an
active immune response was taking place in the MS brain lesion
.
In this report,
we
further characterize the cell populations in the MS plaque, and find TNF+ cells
present.
Using single and double immunohistocytochemistry techniques, we identified
the
TNF+ cells as astrocytes as well as macrophages
.
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Tissue
Samples
.
￿
Six
cases ofMS were studied
.
The postmortem autopsy tissues came from
patients
diagnosed as having either the progressive or relapsing-remitting form of the dis-
ease.
Tissues were obtained from the peri-ventricular white matter of frontal, temporal, or
occipital
lobes regions
.
The MS lesions included in this study were chronic, active plaques
based
on the morphological criteria (5)
.
Six normal control brain tissues were obtained at
autopsy
from adult patients who died ofnonbrain-related disease and demonstrated no visible
plaques.
Other neurologic diseases studied included six cases ofAlzheimer's disease and one
case
of subacute sclerosing panencephalitis (SSPE)
.
The tissues used in this study were frozen
within
10 h of death
.
Tissue
Processing
.
￿
Autopsy
specimens were snap frozen in liquid nitrogen and then stored
at
-80°C
.
Cryostat sections, 8-10 Am thick, were cut, air dried overnight, and fixed in ace-
tone
(reagent grade) for 5 min at 25°C
.
Antibodies
Used
.
￿
Both
rabbit polyclonal TNF (kindly supplied by Genetech, S
.
San Fran-
cisco,
CA) and mouse monoclonal TNF (kindly supplied by Cetur Corp
.,
Emeryville, CA)
were
titrated on PHA-activated PBMC to determine the optimal concentrations
.
The anti-
macrophage
antibodies, CD-11C (monoclonal IgGl
;
Becton Dickinson & Co
.,
Mountain View,
CA)
and HAM56 (monoclonal IgM
;
Enzo Biochem, Inc
.,
New York, NY), and anti-HLA-Dr
(Becton
Dickinson & Co
.)
are routinely used in this laboratory and were tested on a wide
variety
oftissues to determine cell specificity and optimal antibody concentration
.
Both CD-
11C
and HAM 56 stainmonocytes, macrophages, microglia, and resident tissue macrophages
(e.g.,
Kuppfer cells, alveolar macrophages)
.
HAM 56 also stains endothelial cells
.
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rabbit antiglial fibrillary acidic protein was obtained from Dakopatts, Carpenteria, CA. Ir-
relevant antibodies were used as controls for monoclonal and polyclonal antibodies. Negligible
background was observed.
Immunoperoxidase Single-staining Procedure.
￿
This method has been described extensively (6).
Briefly, frozen sections were incubated with primary antibody for 30 min at 25°C for poly-
clonal TNF and 371C for monoclonal TNF in a humidified chamber. Subsequently, the biotin-
labeled secondary antibody was used, either biotin-conjugated horse anti-mouse IgG, goat
anti-mouse IgM, or goat anti-rabbit Ig (Vector Laboratories, Inc., Burlingame, CA) de-
pending on the nature of the primary antibody used. Tissue sections were then incubated
in a complex of StreptAvidin horseradish peroxidase (Biogenex, San Ramon, CA) for 20
min and the colored substrate amino-ethyl carbazole (AEC) was applied. The slides were
then counterstained with Mayer's hematoxylin and coverslipped.
Double-staining Procedure.
￿
The double-staining method is a modification ofa technique pre-
viously reported (4). Frozen sections were treated with the primary antibody for 30 min.
Subsequently, the slides were incubated with biotinylated horse anti-mouse affinity-purified
antibody (Vector Laboratories, Inc.) at 1 :100 for 30 min. The slides were then exposed to
the StreptAvidin horseradish peroxidase for 20 min. After this incubation, the slides were
exposed to diaminobenzidine (DAB) (dark brown precipitate). At this point, the second pri-
mary mAb was applied to the section for 30 min. Subsequently, biotinylated goat anti-rabbit
Ig (Vector Laboratories, Inc.) was added to the slide for 30 min followed by a 20-min incuba-
tion with B-galactosidase-conjugated StreptAvidin (Biogenex). The substrate, consisting of
20 mg/ml 5-bromo-4-chloro-3-indolyl-B-D-galactopyranoside in NN dimethyl formamide,
10 mM NaP04, pH 7.2, 0.15 M NaCl, 1.0 MM MgC12, was added for 15 min at 37°C . The
slides were then washed in tap waterfor 10 min and mounted in glycerol/gelatin. No nuclear
counterstain was used to avoid difficulty in interpreting three-color tissue preparations. Con-
trol slides included the omission of the second primary antibody; we observed no blue staining
in these controls, indicating that the second secondary reagent did not bind to any of the
previously applied reagents in the first part of the staining procedure. Other controls included
double staining with anti-T cell and antimacrophage antibodies to identify background double
staining. All controls were performed initially on human tonsil and then on MS brain tissue,
based on the knowledge that brain tissue may have unique background staining characteristics.
Analysis of Staining Pattern.
￿
For MS tissues, the areas examined were in the center of the
plaque, the edge of the plaque, and the adjacent white matter. In SSPE tissues, the lesions
and white matter adjacent to the demyelinated area were evaluated. In normal brain, white
matter and cortex was examined; in Alzheimer's disease, hippocampus was analyzed. Double-
staining results were calculated as follows: a 1-mm2 grid was placed on three to five different
fields at the outer edge of the plaque, chosen because this area had the greatest number of
TNF' cells. The cells within the grid, ranging from 10 to 50 cells/mm2, were identified as
blue, brown, or double staining. A total of 200 stained cells were counted for each group;
the percent positive was calculated as the number of single or double-staining cells divided
by the total number of staining cells.
Results
The MS lesions examined included chronic active plaques and adjacent white matter.
To identify and localize the MS plaque edge, cryostat sections were stained with
anti-HLA-Dr. Class H antigens have been shown to be most dense at the edge of
chronic active plaque lesions (Fig. 1 a). Six MS specimens were then stained with
monoclonal and polyclonal antiTNF The results demonstrate that TNF + cells were
most numerously distributed at the lesion edge, with very few positive cells within
the plaque. The majority of TNF+ cells were morphologically identified as reactive
fibrous astrocytes based on their characteristic spherical or ellipsoidal nuclei, with
numerous fine cytoplasmic processes. Adjacent sections stained with anti-GFAP
demonstrated morphologically characteristic reactive astrocytes at the lesion edge.HOFMAN ET AL.
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FIGURE 1.
￿
Chronic active plaque lesion fromMS
tissue stained with specific antibodies using im-
munoperoxidase procedures on frozen sections .
(a) High density of anti-HLA-Dr staining cells
outlines the plaque edge . Positive cells are red
(ARC precipitate). Subsequent photomicrographs
focuson theenclosed plaque edge area (x 80). (b)
Double staining with antiTNF (brown) and
HAM56 (blue) at the lesion edge demonstrates
predominant single-staining cells (x200) . (c)
Double stainingwith antiTNF(brown)and anti-
GFAP (blue) shows positive cells for both markers
(arrow) (x200) .
In the one case of SSPE, which exhibited severely gliotic white matter with high
numbers of perivascular leukocytes, TNF+ cells with astrocyte characteristics were
also present in the diseased area, Six cases of Alzheimer's disease and six normal
control brain specimens did not exhibit antiTNF staining .
To determine whether the TNF staining was associated with the macrophages
present at the lesion site, two sets of double-staining studies with antiTNF and an-
timacrophage antibodieswere performed . In double staining with monoclonal anti-
TNF and antimacrophage HAM56, the majority ofcells exhibit single staining, in-
dicating that the majority of TNF+ cells were not macrophages (Table I) . On a
secondMS specimen, similar resultswere obtained with an alternative double-staining
combination, usingpolyclonal antiTNF and monoclonal anti-CD11C (Table I) . Fig.
1 B shows the results of double staining at the lesion edge .
Double-staining experiments were performed using anti-GFAP and antiTNF to
confirm the TNF association with astrocytes . In one experiment, shown in Fig . 1
c, GFAP+ cells (blue) comarked with TNF (brown), indicating double-staining cells.610
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TABLE I
Double Staining for TNF and Macrophage Markers
Percent positive
Double
Exp.
￿
TNF Macrophage staining
I
￿
TNF + macrophage
￿
11
￿
88
￿
1
II
￿
Macrophage + TNF
￿
25
￿
68
￿
7
The great majority ofpositive cells were GFAP, as expected. Counting single- and
double-stainingcells wasvery difficult andnotclear because astrocytes havenumerous
processes throughout the different layers of tissue.
Discussion
The presence of TNF+ cells at the MS lesion site, strongly suggests that an ac-
tive immune response with participating stimulatedleukocytesandglialcellsistaking
place. Recently, a report by Merrill et al. (7) has shown that in MS patients, the
levels ofTNF and IL-1 are increased in the blood and spinal fluid. These studies
suggest that TNF may be relevant in MS in disease development. TNF has been
reported tohave awide range offunctions, including theinductionofIL-1 secretion
(8)and enhancement ofmonocyte cytotoxicity(9). Studies havealso shown thatTNF
can function synergisticallywith IL-1 and IFN--y (10, 11) to augment monocyte/mac-
rophage cytotoxicity. Recent reports have demonstrated that TNF may participate
in destruction of oligodendroglial cells and the degeneration of the myelin sheath
(12, 13). Thus, TNFis implicated directly indemyelination orindirectly by activating
a cell-mediated cytotoxicity process.
Double-staining studies indicate that TNF is predominantly associated with as-
trocytes in the MS lesion. Although TNF is produced by activated macrophages,
recent studies have suggested that activated astrocytes (12) and microglial cells (14)
can alsosynthesize and secretethis cytokine. Astrocytes have many functional prop-
erties similar to those of macrophages, such as class II antigen expression (15), an-
tigen presentation (16), PGE, and IL-1 secretion (17, 18). Thus, the astrocytes in
the MS lesion, which are likely to be activated based on class II antigen expression,
may also be responsible for the production of THE These immunocytochemical
studies showing TNF binding to astrocytes do not identify the cellular source of
this cytokine. Thus, macrophages may indeed be producing TNF, while the astro-
cytes may be the target cell for binding and internalization of this factor. Further
experiments using molecular probes to determine the cellular source of TNF are
underway.
TNF+ cells were also detected in the virally induced disease SSPE, but not in
Alzheimer's disease ornormal CNStissue. SSPE brain often exhibits inflammatory
cell infiltration, whichcorrelates with the site ofdemylination. Our studieshave shown
that in SSPE, class II antigen expression on astrocytes as well as macrophages was
prevalent (data not shown). This cell marker pattern was clearly reminiscent of the
MS lesion. Since TNF+ cells were also found in SSPE, we hypothesize that TNF
may be universally involved in inflammatory cell-related demyelination.HOFMAN ET AL.
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In summary, this study demonstrates that TNF is present at the MS lesion site
and is associated with the astrocytes at the plaque edge. This cytokine is also found
in another neurological disease that demonstrates inflammatory cell infiltration. These
data suggest that TNF may be produced during an active immune response in the
CNS and is involved in demyelination and disease progression.
Summary
Frozen brain specimens from patients with multiple sclerosis (MS) and other neu-
rologic diseases were analyzed using immunocytochemical techniques for the pres-
ence of TNF. In brain lesions in MS, and subacute sclerosing panencephalitis,
TNF` cells were demonstrated. At the lesion site in MS, TNF+ staining is associated
with both astrocytes and macrophages. These observations were not made in Alz-
heimer's disease or normal brain tissue. The presence ofTNF in MS lesions suggests
a significant role for cytokines and the immune response in disease progression.
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